Study Finds Zithromax May Carry Higher Risk of Cardiovascular Death

A recent study has caused the FDA to warn that Zithromax antibiotic made by Pfizer Inc. may cause a “small increase” in the risk of cardiovascular death compared with another common antibiotic. The study states that the antibiotic which is used to treat infections, caused a “small absolute increase in cardiovascular deaths” among patients, particularly those who had a higher chance of heart problems, according to the study published today in the New England Journal of Medicine.
To read the FDA’s full warning, click here
Zithromax (azithromycin): FDA Statement on risk of cardiovascular death
FDA notified healthcare professionals that it is aware of the study published in the New England Journal of Medicine May 17, 2012 reporting a small increase in cardiovascular deaths, and in the risk of death from any cause, in persons treated with a 5-day course of azithromycin (Zithromax) compared to persons treated with amoxicillin, ciprofloxacin, or no drug. FDA is reviewing the results from this study and will communicate any new information on azithromycin and this study or the potential risk of QT interval prolongation after the agency has completed its review.
BACKGROUND: Azithromycin belongs to a class of antibacterial drugs called macrolides, which have been associated with cardiovascular effects; specifically, prolongation of the QT interval. In 2011, FDA reviewed macrolide drug labeling information related to QT interval prolongation and TdP. The WARNINGS AND PRECAUTIONS section of the Zmax drug label (azithromycin extended release for oral suspension) was revised in March 2012 to include new information regarding risk for QT interval prolongation, which appears to be low. The drug labels for clarithromycin and erythromycin also contain information about QT interval prolongation in the WARNINGS section. FDA is in the process of updating risk information in the drug labels for additional macrolide antibacterial drugs.
RECOMMENDATION: Patients taking azithromycin should not stop taking their medicine without talking to their healthcare professional. Healthcare professionals should be aware of the potential for QT interval prolongation and heart arrhythmias when prescribing or administering macrolides.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program:

SHARE THIS ARTICLE

Get Help Now

Fill this out for a FREE case review.

Getting Started

Briefly type in what happened.
That’s all it takes to start the conversation, and, together, we will decide if Terrell • Hogan is the injury and wrongful death law firm to help you.

Sending your message means you are familiar with the purpose of this website.

About The Author

Laura Hack

Laura Hack

Laura Hack is a paralegal with Terrell • Hogan. She has been with the firm since 1996 and has worked primarily for Wayne Hogan. She is an experienced Paralegal with 30+ years of working in the law practice industry. Skilled in Appeals, Civil Trial Litigation Support, Torts, Trial Practice, and Pleadings.